Search

Your search keyword '"Nisreen M.A. Okba"' showing total 2 results
Start Over Author "Nisreen M.A. Okba" Publisher american association for the advancement of science (aaas)
2 results on '"Nisreen M.A. Okba"'

1. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Author

Gestur Vidarsson, Mathieu Claireaux, Ilja Bontjer, Marlies M. van Haaren, Alex van der Kooi, Philip J. M. Brouwer, Jelle van Schooten, Niels van der Velde, Ronald Derking, Karlijn van der Straten, Denise Guerra, Gius Kerster, Andrew B. Ward, Jonathan L. Torres, W. Joost Wiersinga, Neeltje A. Kootstra, Sandhya Bangaru, Tom P. L. Bijl, Aafke Aartse, Edith E. Schermer, Judith A. Burger, Kirsten D. Verheul, Bart L. Haagmans, Mariëlle J. van Breemen, Tom G. Caniels, Marit J. van Gils, Yoann Aldon, Nisreen M.A. Okba, Godelieve J. de Bree, Kwinten Sliepen, Jonne L. Snitselaar, Rogier W. Sanders, Arthur E. H. Bentlage, Virology, AII - Infectious diseases, Graduate School, Medical Microbiology and Infection Prevention, APH - Aging & Later Life, Experimental Immunology, Infectious diseases, Center of Experimental and Molecular Medicine, AII - Inflammatory diseases, AII - Cancer immunology, Landsteiner Laboratory, and APH - Global Health

Subjects
Male, 0301 basic medicine, Vulnerability, Antibody Affinity, Antibodies, Viral, medicine.disease_cause, Epitope, Epitopes, 0302 clinical medicine, Immunophenotyping, skin and connective tissue diseases, Antigens, Viral, Research Articles, Coronavirus, Multidisciplinary, biology, Antibodies, Monoclonal, Microbio, Middle Aged, 030220 oncology & carcinogenesis, Spike Glycoprotein, Coronavirus, Receptors, Virus, Female, Antibody, Coronavirus Infections, Research Article, Adult, Coronavirus disease 2019 (COVID-19), medicine.drug_class, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Pneumonia, Viral, Protein domain, B-Lymphocyte Subsets, Somatic hypermutation, Monoclonal antibody, Betacoronavirus, 03 medical and health sciences, Protein Domains, Antigen, Cell Line, Tumor, medicine, Humans, Protein Interaction Domains and Motifs, Pandemics, Aged, SARS-CoV-2, R-Articles, Spike Protein, COVID-19, Antibodies, Neutralizing, Virology, 030104 developmental biology, biology.protein, Immunologic Memory, Broadly Neutralizing Antibodies, Receptors, Coronavirus
Abstract

Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al. isolated 403 monoclonal antibodies from three convalescent COVID-19 patients. They show that the patients had strong immune responses against the viral spike protein, a complex that binds to receptors on the host cell. A subset of antibodies was able to neutralize the virus. Competition and electron microscopy studies showed that these antibodies target diverse epitopes on the spike, with the two most potent targeting the domain that binds the host receptor. Science , this issue p. 643

Published
2020
Full Text
View/download PDF

2. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

Author

Judith M. A. van den Brand, Saskia L. Smits, Asisa Volz, Peter Wohlsein, Wolfgang Baumgärtner, Debby Schipper, Theo M. Bestebroer, Robert Fux, V. Stalin Raj, Albert D. M. E. Osterhaus, Gerd Sutter, Albert Bensaid, Nisreen M.A. Okba, David Solanes Foz, Bart L. Haagmans, Thijs Kuiken, Joaquim Segalés, Virology, and Plazi

Subjects
0301 basic medicine, viruses, Antibodies, Viral, medicine.disease_cause, Disease Outbreaks, chemistry.chemical_compound, Viral, Orthopoxvirus, Viridae, Non-U.S. Gov't, Neutralizing, Multidisciplinary, biology, Research Support, Non-U.S. Gov't, Viral Vaccine, biotic associations, corona viruses, virus diseases, covid, Spike Glycoprotein, Virus Shedding, covid-19, TheoryofComputation_LOGICSANDMEANINGSOFPROGRAMS, Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus, RNA, Viral, Coronavirus Infections, CETAF-taskforce, Camelus, Camelpox virus, Coronaviridae, Middle East respiratory syndrome coronavirus, Vaccinia virus, Research Support, Antibodies, Virus, virus-host, Microbiology, 03 medical and health sciences, SDG 3 - Good Health and Well-being, pathogen-host, Journal Article, medicine, Animals, Humans, biotic relations, Viral shedding, ComputingMilieux_THECOMPUTINGPROFESSION, Outbreak, pathogens, Viral Vaccines, biochemical phenomena, metabolism, and nutrition, biotic interaction, biology.organism_classification, Antibodies, Neutralizing, Virology, respiratory tract diseases, Coronavirus, TheoryofComputation_MATHEMATICALLOGICANDFORMALLANGUAGES, 030104 developmental biology, chemistry, RNA, Vaccinia
Abstract

Coronaviruses in the Middle East Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe acute respiratory illness and kills about a third of people infected. The virus is common in dromedary camels, which can be a source of human infections. In a survey for MERSCoV in over 1300 Saudi Arabian camels, Sabir et al. found that dromedaries share three coronavirus species with humans. Diverse MERS lineages in camels have caused human infections, which suggests that transfer among host species occurs quite easily. Haagmans et al. made a MERS-CoV vaccine for use in camels, using poxvirus as a vehicle. The vaccine significantly reduced virus excretion, which should help reduce the potential for transmission to humans, and conferred cross-immunity to camelpox infections. Science , this issue p. 81 , p. 77

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results